TABLE 3.
Partial List of Clinical Trials Evaluating PET-Directed Therapy in Hodgkin Lymphoma
| Study group | Stage | PET intervention | Phase |
|---|---|---|---|
| EORTC-GELA-IIL | Localized | No RT if PET results are negative after 2 cycles of ABVD | 3 |
| UK NCRI lymphoma group | Localized | No RT if PET results are negative after 3 cycles of ABVD | 3 |
| GHSG | Localized | No RT if PET results are negative after 2 cycles of ABVD | 3 |
| GITIL | Advanced | escBEACOPP if PET results are positive after 2 cycles of ABVD | 3 |
| UK NCRI lymphoma group | Advanced | escBEACOPP if PET results are positive after 2 cycles of ABVD | 2 |
| IIL | Advanced | Salvage therapy if PET results are positive after 2 cycles of ABVD | 3 |
| GHSG | Advanced | escBEACOPP reduced to 4 cycles if PET results are negative after 2 cycles | 3 |
| GELA | Advanced | escBEACOPP reduced to ABVD if PET results are negative after 2 cycles | 3 |
BVD = doxorubicin, bleomycin, vinblastine, dacarbazine; EORTC = European Organisation for Research and Treatment of Cancer; escBEACOPP = escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; GELA = Groupe d'Etude des Lymphomes de l'Adulte; GHSG = German Hodgkin Study Group; GITIL = Gruppo Italiano Terapie Innovative nei Linfomi; IL = Intergruppo Italiano Linfomi; PET = positron emission tomography; RT = radiotherapy; UK NCRI = United Kingdom National Cancer Research Institute.